Novel test from T2 Biosystems identifies five species of Candida, one of the most lethal forms of sepsis-causing bloodstream infections, providing results in hours instead of days.
With recertification performed by the British Standards Institute, COLA continues as the only CMS-deemed accreditor with an ISO quality systems designation.
Thermo Fisher Scientific has completed FDA listing of its Ion PGM Dx next-generation sequencing system as Class II medical device.
NanoString Technologies has introduced the PanCancer immune profiling panel, a highly multiplexed gene expression panel for the nCounter analysis system that will enable researchers to create profiles of the human immune response to various forms of cancer.
A study demonstrates that use of a molecular test by bioTheranostics results in cost savings for ER+ breast cancer patients by optimizing initial chemotherapy and extended endocrine therapy after 5 years.
French theranostics and in vitro diagnostics firm Theradiag continues its pursuit to develop a microRNA theranostic kit for rectal cancer.
Abbott Diagnostics has introduced the mView performance monitoring subscription for its m2000 molecular diagnostics system. The web-based dashboard offers configurable reports to automate data analysis and measure laboratory efficiency.
A new study in the journal Cancer finds that Myriad’s myRisk hereditary cancer test identifies 43% more patients with breast cancer risk.
The companies’ partners will take aim at transforming pathology workflow, addressing industry challenges related to case reporting, integration of molecular and genetic technologies, and synoptic reporting.
A study presented at ICAAC 2014 finds that the clinical testing volume and positivity rate of the chikungunya virus both grew after the first case spread to the Western Hemisphere this year.